Answer
Caution and adverse-event monitoring are recommended because eribulin mesylate mildly inhibits CYP3A4 in vitro, while tacrolimus has a narrow therapeutic window and is eliminated mainly through CYP3A4-mediated metabolism; no in vivo interaction data are available.
Sources for this answer
- Eribulin Eisai 0.44 mg/ml solution for injectionEisai Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 26Document updated
Sources checked